Organization Overview
Alternative names
naltrexone (revia) (2014)
alemtuzumab (campath) (1 trial)
allogeneic blood cells (1 trial)
allogeneic hematopoietic stem cells (Hemacord) (2 trials)
allogeneic stem cells (1 trial)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (3 trials)
cyclophosphamide (cytoxan) (2 trials)
cyclosporine (sandimmune) (3 trials)
filgrastim (neupogen) (1 trial)
fludarabine (fludara) (6 trials)
Arterial Occlusive Diseases (Phase 3)
Arthritis (Phase 4)
Arthritis, Rheumatoid (Phase 4)
Brain Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinosarcoma (Phase 2)
Cholangiocarcinoma (Phase 3)
Colorectal Neoplasms (Phase 2)
Diabetic Foot (Phase 3)
Disease (Phase 2)
Esophageal Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 3)
Glioblastoma (Phase 2)
Glioma (Phase 3)
Graft vs Host Disease (Phase 2)
Hematologic Diseases (Phase 2)
Hematologic Neoplasms (Phase 2)
Hemoglobinopathies (Phase 2)
Ischemia (Phase 3)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 4)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 4)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myelomonocytic, Juvenile (Phase 2)
Melanoma (Phase 3)
Metabolism, Inborn Errors (Phase 2)
Mixed Tumor, Mullerian (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 3)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Pancytopenia (Phase 2)
Preleukemia (Phase 2)
Psoriasis (Phase 1)
Rectal Neoplasms (Phase 3)
Syndrome (Phase 2)
Urinary Bladder Neoplasms (Phase 3)